Table 4 Effect of baseline characteristics on GC prescriptions according to prescriber tendency

Demographics

Age (decades)

1.15, 1.11–1.20^*

1.26, 1.23–1.29^*

<0.001

Gender (female)

0.98, 0.87–1.10

0.89, 0.82–0.97^*

0.211

Current smoker (versus never)

1.09, 1.02–1.17^*

1.07, 1.02–1.13^*

0.744

GC-associated comorbidities

Osteoporosis

1.49, 1.14–1.95^*

1.84, 1.50–2.25^*

0.225

Avascular necrosis

2.28, 0.32–16.22

1.84, 0.36–9.51

0.870

Myopathy

2.29, 0.57–9.15

1.23, 0.45–3.38

0.479

Diabetes mellitus

0.88, 0.72–1.08

1.02, 0.88–1.18

0.257

Cardiovascular disease

1.38, 1.04–1.84^*

1.62, 1.31–2.00^*

0.373

Hypertension

1.08, 0.95–1.24

1.29, 1.17–1.41^*

0.039

Hyperlipidaemia

1.10, 0.92–1.31

1.07, 0.94–1.22

0.829

Peptic ulcer disease

1.36, 1.06–1.74^*

1.33, 1.09–1.63^*

0.910

Pancreatitis

1.00, 0.49–2.05

1.44, 0.81–2.54

0.442

Depression

1.09, 0.96–1.23

1.09, 0.99–1.20

0.994

Insomnia

1.27, 1.08–1.50^*

1.36, 1.20–1.54^*

0.548

Psychosis

1.14, 0.60–2.17

1.29, 0.78–2.14

0.767

Prior use

GC prescription prior to follow up

6.52, 5.51–7.71^*

11.76, 10.24–13.51^*

<0.001